Candel Therapeutics (CADL) Cash from Investing Activities (2020 - 2025)
Candel Therapeutics' (CADL) quarterly Cash from Investing Activities came in at -$409000.0 in Q4 2025, down 13533.33% year-on-year from N/an in Q4 2024, and down 249.57% quarter-over-quarter from -$117000.0 in Q3 2025.
Candel Therapeutics (CADL) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Candel Therapeutics has disclosed Cash from Investing Activities across 6 years of filings, most recently posting -$409000.0 for Q4 2025.
- Cash from Investing Activities for Q4 2025 came in at -$409000.0, down 13533.33% year-over-year; the trailing twelve-month figure through Dec 2025 was -$560000.0 (down 3400.0% YoY), and the FY2025 annual result was -$560000.0, down 3400.0% from the prior year.
- Cash from Investing Activities came in at -$409000.0 for Q4 2025 at Candel Therapeutics, down from -$117000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $19000.0 in Q1 2023 to a low of -$710000.0 in Q2 2021.
- The 5-year median for Cash from Investing Activities is -$169000.0 (2023), against an average of -$209894.7.
- Across the five-year window, Cash from Investing Activities jumped 111.11% in 2023 and slumped 13533.33% in 2025, its largest moves.
- Candel Therapeutics' Cash from Investing Activities stood at -$504000.0 in 2021, then soared by 45.24% to -$276000.0 in 2022, then jumped by 90.22% to -$27000.0 in 2023, then jumped by 88.89% to -$3000.0 in 2024, then plunged by 13533.33% to -$409000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$409000.0 (Q4 2025), -$117000.0 (Q3 2025), and -$31000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - | -409,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -409,000.00 |
| Dec 31, 2025 | -409,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Sep 30, 2023 | -103,000.00 |
| Sep 30, 2023 | -103,000.00 |
| Jun 30, 2023 | -169,000.00 |
| Jun 30, 2023 | -169,000.00 |